FDA — authorised 28 August 1972
- Marketing authorisation holder: BAXTER HLTHCARE
- Status: approved
🇺🇸 Efrane in United States
FDA authorised Efrane on 28 August 1972
Marketing authorisations
FDA — authorised 28 August 1972
- Application: NDA017087
- Marketing authorisation holder: BAXTER HLTHCARE
- Local brand name: ETHRANE
- Indication: LIQUID — INHALATION
- Status: approved
FDA — authorised 27 July 1987
- Application: ANDA070803
- Marketing authorisation holder: ABBOTT
- Local brand name: ENFLURANE
- Indication: LIQUID — INHALATION
- Status: approved
FDA — authorised 29 July 1994
- Application: ANDA074396
- Marketing authorisation holder: PIRAMAL CRITICAL
- Local brand name: ENFLURANE
- Indication: LIQUID — INHALATION
- Status: approved
Efrane in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Metabolic approved in United States
Frequently asked questions
Is Efrane approved in United States?
Yes. FDA authorised it on 28 August 1972; FDA authorised it on 28 August 1972; FDA authorised it on 27 July 1987.
Who is the marketing authorisation holder for Efrane in United States?
BAXTER HLTHCARE holds the US marketing authorisation.